2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Imaging, Molecular Testing, Cell Expansion, Treatment Considerations, Combination Therapy, Drug Development, Drug-Drug Interactions, Supportive Care, Therapy Sequence, Biological Therapies, Antibody Therapy, Bispecific Antibody Therapy, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Immunotherapy, Monoclonal Antibody Therapy, Non-Biological Therapies, Chemotherapy, Pharmacology, Adverse Events, Biological Processes, Immune Mechanism, Clinical Practice (Health Services and Quality), Health Economics, Patient Safety, Practice Models, Quality Improvement, Quality of Care, Value, Diseases, Immunology, Immunodeficiency, Infectious Diseases, Viral, Bacterial, Fungal, Other Pathogens, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Metabolic Disorders, Measurable Residual Disease, ALL, CLL, Non-Hodgkin Lymphoma, B Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Elderly, Young Adult
PAPER

6239 Impact of IKZF1 deletion on prognosis and treatment response to inotuzumab ozogamicin in B-ALL: A multicenter OK-1 cohort study

Jiaxin Zheng, Fen Zhou, MD, PhD2, Feifei Tang, MD, PhD3, Zhixiang Wang4, Bailin He5, Wenhao Zhong6, Ye Jieyu7, Heng Mei, MD, PhD8, Hongsheng Zhou9
1 Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China
2 Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
3 Peking University People’s Hospital, Beijing, China
4 Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China
5 Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China
6 Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China
7 Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China
8 Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
9 Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China

Background: IKZF1 deletion is a high-risk genetic feature in B-cell acute lymphoblastic leukemia (B-ALL) associated with poor survival. Inotuzumab ozogamicin (InO) has demonstrated efficacy in relapsed/refractory (R/R) B-ALL. However, real-world evidence regarding whether InO can overcome the adverse prognosis conferred by IKZF1 deletion remains limited.

Methods: This multicenter retrospective study included B-ALL patients treated with InO between June 2022 and September 2025. The safety cohort comprised 109 patients who received ≥1 dose. The efficacy cohort (n=82) included patients with known IKZF1 status (27 deleted, 55 wild-type), excluding those with mixed-phenotype acute leukemia and those treated with InO as induction/consolidation therapy.Patients were stratified as R/R (n=46), MRD-positive (n=15), or extramedullary disease (EMD, n=21). Outcomes included CR/CRi, MRD negativity, overall survival (OS), and progression-free survival (PFS).

Results: In the overall efficacy cohort, the median age was 34 years (range, 13–70). The CR/CRi rate was 81.5% (22/27) in the IKZF1 deletion group and 65.5% (36/55) in the wild-type group (P=0.197). With a median follow-up of 20.9 months,(95% CI:12.67–20.87months), the 2-year PFS was 53.5% versus 39.4% (P=0.302), and the 2-year OS was 82.5% versus 76.1% (P=0.876) for IKZF1 deletion versus wild-type, respectively.In the R/R subgroup, the CR/CRi rate was 80.0% (12/15) in the IKZF1 deletion group versus 80.6% (25/31) in the wild-type group. The median OS was not reached in either group. The median PFS was 13.9 months (95% CI: 2.3 months–not reached) in the IKZF1 deletion group versus 16.7 months (95% CI: 4.9 months–not reached) in the wild-type group (P=0.830). Univariate analysis revealed no significant association between IKZF1 deletion and OS (HR=1.77, 95% CI: 0.47–6.63, P=0.399) or PFS (HR=1.10, 95% CI: 0.47–2.57, P=0.826).In the MRD-positive subgroup , InO induced MRD negativity in 66.7% (6/9) of IKZF1 deletion patients and 50.0% (3/6) of wild-type patients. The 1-year PFS was 88.9% (8/9) versus 50.0% (3/6), respectively.In the EMD subgroup, although the small number of IKZF1 deletion cases (n=3) precluded statistical comparison, 1 patients achieved complete remission and 2 achieved partial EMD response.A total of 21 patients (7 with IKZF1 deletion, 14 wild-type) successfully received bridging therapy (12 to allogeneic hematopoietic stem cell transplantation, 9 to chimeric antigen receptor T-cell therapy). The bridging rate was comparable between the IKZF1 deletion (25.9%) and wild-type (25.5%) groups.Patients who underwent bridging in the IKZF1 deletion group had favorable 2-year PFS compared with the wild-type group (85.7% vs. 53.6%, P=0.23).In the safety cohort (N=109), the incidence of sinusoidal obstruction syndrome (SOS/VOD) was 2.8% (n=3). No treatment-related deaths occurred.

Conclusion: In this real-world cohort, InO demonstrated robust efficacy in IKZF1-deleted B-ALL, achieving CR and deep MRD negativity rates comparable to those in wild-type patients. InO effectively served as a bridge to HSCT or CAR-T, enabling high-risk IKZF1 deletion patients to access curative-intent therapies. These findings suggest that InO may overcome the adverse prognosis associated with IKZF1 deletion.

Fen Zhou, MD, PhD: No relevant conflicts of interest to declare.